-
-
Call more information
660-596-2224 -
Author: Amanda Burden, MD, FASA, FSSH ASA Monitor June 2024, Vol. 88, 9–10. Case presentation A 60-70-year-old ASA Physical Status 4 woman with a BMI of 36.9 and past medical history significant for coronary artery disease (CAD), status post-myocardial infarction (MI) and coronary artery bypass graft (CABG), congestive heart failure (CHF), asthma, chronic obstructive pulmonary […]
Read MoreAuthor: Muhammad A. Farooq Anwar, MD, MBA et al ASA Monitor June 2024, Vol. 88, 1–6. The IOM report “Relieving Pain in America” indicates that racial and socioeconomic disparities in pain treatment are common. There is a paucity of data regarding disparities in innovative pain procedures. Two existing studies discuss profound racial differences in patients receiving […]
Read MoreNovel gene therapy reduces risk of motor impairment in MLD The FDA has approved Lenmeldy (atidarsagene autotemcel) as the first gene therapy for children with presymptomatic late infantile, pre-symptomatic early juvenile, or early symptomatic early juvenile metachromatic leukodystrophy (MLD). MLD is a rare genetic disease affecting the brain and nervous system due to a deficiency […]
Read MoreASA Monitor June 2024, Vol. 88, 8. A 49-year-old female was scheduled for an urgent transesophageal echo (TEE) to rule out intracardiac thrombosis before cardioversion due to new onset atrial fibrillation with rapid ventricular rate. At this institution, the TEEs are done in a procedure room without an anesthesia machine under TIVA sedation, with necessary back […]
Read MoreASA Monitor June 2024, Vol. 88, 7 Recently, researchers compared ejection fraction values derived from conventional two-dimensional (2D) transthoracic echocardiography to those generated by a wearable device that uses acoustic sensors, electrocardiographic signals, and machine learning to generate a value. How did the measurements from the wearable device MOST likely compare to those derived from 2D […]
Read More